LGG Probiotic Safety in Special Populations: What the Research Shows About Infants, Older Adults, Pregnancy, and Critically Ill People (2026)

Lactobacillus rhamnosus GG, usually shortened to LGG, is the single most clinically studied probiotic strain, and for most healthy people it has an excellent safety record built over decades of use. But safety is never a single answer that applies equally to everyone. A healthy adult, a premature infant in intensive care, and a person with a central venous line are not in the same situation, and honest guidance has to reflect that. This article reviews what the published research actually shows about LGG safety across populations, where the record is genuinely reassuring, and where real, documented caution applies. The goal is not to alarm and not to reassure blindly, but to lay out the evidence so you can make an informed decision.

The General Safety Record in Healthy People

For healthy adults and children, the direct safety evidence on LGG is reassuring. In a phase I study, LGG at 10 billion colony-forming units twice daily for 28 days in healthy elderly volunteers aged 66 to 80 was safe and well tolerated, with no evidence of harm [Hibberd 2014 PMID 25438151]. This is a small study of 15 people rather than a large trial, but it is a clean LGG-specific safety signal in an older population that is often assumed to be more vulnerable.

The most compelling population-level reassurance comes from Finland. During the 1990s, national consumption of LGG rose sharply as it became a common addition to dairy products. Nationwide surveillance found that despite this rapid rise in LGG use, there was no corresponding increase in Lactobacillus bacteremia, meaning bloodstream infections caused by these bacteria did not climb even as far more people were consuming the strain [Salminen 2002 PMID 12410474]. When researchers then examined the Lactobacillus bloodstream infections that did occur, they found that these cases clustered overwhelmingly in patients who already had serious underlying illness [Salminen 2004 PMID 14679449].

The expert consensus mirrors this pattern. A comprehensive safety review concluded that probiotics have a long history of safe use and are generally safe for most people, while acknowledging that real risks, including systemic infection, exist in susceptible individuals and are inconsistently captured in trials [Doron 2015 PMID 25922398]. The honest summary of the general picture is that LGG is safe for the large majority, and that the exceptions are specific and identifiable.

Where Genuine Caution Applies: Immunocompromised and Critically Ill People

The exceptions are not hypothetical. There is a documented, strain-specific literature showing that in the wrong host, ingested probiotic bacteria can enter the bloodstream.

The landmark cautionary report described two children who developed Lactobacillus sepsis attributable to probiotic therapy, one of whom had short-gut syndrome. Molecular fingerprinting showed the bacteria in the bloodstream were indistinguishable from the ingested probiotic strain, directly linking the infection to the supplement [Land 2005 PMID 15629999]. An earlier case documented a liver abscess caused by an L. rhamnosus strain that was molecularly indistinguishable from LGG specifically [Rautio 1999 PMID 10452653].

More recent genomic work has made the mechanism undeniable. In a study of intensive care patients, researchers used whole-genome sequencing to show direct transmission of LGG from probiotic capsules into the bloodstream, with blood isolates inseparable from the probiotic product. Bacteremia occurred in 6 of 522 LGG-treated ICU patients compared with 2 of 21,652 untreated patients [Yelin 2019 PMID 31700189]. The honest way to read this is with proper proportion: the absolute risk was roughly one percent and confined to critically ill ICU patients, but the strain itself can translocate in that setting, and that is not a theoretical concern.

Critically ill patients also do not appear to benefit. In a large randomized trial of 2,653 mechanically ventilated ICU patients across 44 hospitals, LGG did not reduce ventilator-associated pneumonia, which occurred in 21.9 percent of the LGG group versus 21.3 percent of the placebo group, nor did it improve other important outcomes [Johnstone 2021 PMID 34546300]. When a supplement carries a real, if small, translocation risk in a population and does not deliver benefit in that same population, the risk-benefit math is not favorable.

It is also worth being clear about a widely cited warning that is often misattributed. A trial in patients with predicted severe acute pancreatitis found higher mortality in the probiotic group, 16 percent versus 6 percent [Besselink 2008 PMID 18279948]. Two points of honesty are essential here. First, that trial used a multispecies probiotic mixture, not LGG, so it should never be presented as an LGG finding. Second, that publication carries an official Expression of Concern. It remains the canonical demonstration that probiotics can cause net harm in critically ill patients, which is why it belongs in any honest safety discussion, but it is a general-critical-illness caution, not a strike against LGG specifically.

The practical rule from all of this is direct. People who are immunocompromised, who have a central venous line, who have short-gut syndrome, or who are critically ill should talk to a physician before taking any probiotic, including LGG.

Infants and Preterm Babies: Benefit and a Real 2023 Concern

Probiotics in premature infants are one of the most actively debated areas in the field, because the potential benefit and the potential harm are both real.

On the benefit side, a Cochrane meta-analysis concluded that enteral probiotic supplementation reduces severe necrotizing enterocolitis and all-cause mortality in preterm infants [AlFaleh 2014 PMID 24723255]. LGG-specific evidence in this population exists as well. A randomized trial of oral L. rhamnosus GG in very-low-birth-weight preterm neonates prevented enteric Candida colonization and was tolerated in the monitored intensive care setting [Manzoni 2006 PMID 16705580], and a current strain-specific systematic review has synthesized the LGG preterm evidence for a more up-to-date picture [Ananthan 2024 PMID 39060543].

But the safety concern here is not hypothetical, and it recently became concrete. In September 2023, the United States Food and Drug Administration issued a warning after a premature infant died of sepsis caused by a probiotic organism genomically matched to the product the infant had received. The FDA stated that probiotics given to hospitalized preterm infants can cause invasive, potentially fatal disease, noted more than two dozen reported adverse events since 2018, and emphasized that these probiotics are not FDA-approved drugs for this use [FDA 2023, fda.gov]. In the interest of full honesty, the product involved in that death was a Bifidobacterium product, not LGG, so it would be wrong to say LGG caused it. But the episode is a real illustration that the preterm infant gut is a uniquely vulnerable environment, and a balanced current review lays out exactly this unresolved risk-benefit tension in the post-2023 context [Calvo 2024 PMID 38556491].

The takeaway for parents is that probiotic use in a hospitalized premature infant is a decision for the neonatal medical team, made case by case, and never a do-it-yourself choice.

Pregnancy and Lactation

For pregnancy and breastfeeding, the available evidence is reassuring while being appropriately humble about its limits. A systematic review and meta-analysis of probiotic and prebiotic use during pregnancy and lactation found no significant association with serious adverse pregnancy or infant outcomes, with only minor gastrointestinal effects reported [Sheyholislami 2021 PMID 34371892]. The honest qualifier is that heterogeneity across studies and incomplete safety reporting limit what can be concluded about rare harms, so pregnancy is a reasonable time to confirm any supplement choice with an obstetric provider rather than assume.

Understanding the Regulatory Frame

One point underlies all of the above. LGG, like other probiotics sold to consumers, is regulated as a dietary supplement, not as an FDA-approved drug or licensed live biotherapeutic. There is no approved indication for preventing necrotizing enterocolitis, treating disease in the ICU, or any other medical use. That regulatory status is exactly why the population distinctions in this article matter: a supplement that is well suited to a healthy adult supporting general gut health is not automatically appropriate for a critically ill patient or a premature infant, and the label alone will not make that distinction for you.

The Bottom Line

The evidence supports a nuanced conclusion rather than a slogan. For healthy adults, children, older adults, and people in pregnancy, LGG has a strong and well-documented safety record, backed by population-level surveillance showing that decades of widespread use did not raise bloodstream infection rates. At the same time, there is a real, strain-specific, and honestly documented caution for a defined group: people who are immunocompromised, critically ill, have a central line or short-gut syndrome, and hospitalized premature infants. In those settings the decision belongs with a physician, and in some of them, such as the critically ill, LGG has not shown benefit to justify the risk.

Wise Choice Supplements LGG Probiotic provides 30 billion CFU of Lactobacillus rhamnosus GG per capsule in a delayed-release format, intended to support general gut health in healthy adults. If you fall into any of the vulnerable groups described above, speak with your healthcare provider before starting it or any other probiotic.

This article is for educational purposes and is not medical advice. Supplements are intended to support general wellness and are not intended to diagnose, treat, cure, or prevent any disease. Talk with a qualified healthcare professional before starting any new supplement, especially if you are pregnant, nursing, immunocompromised, critically ill, or caring for an infant.